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1. Introduction 
Skin cancer is one of the most widespread tumours. However, despite the progress achieved 
in all clinical diagnostic techniques, the most severe of those tumours - cutaneous melanoma, 
continues to be an important problem of social health. A large number of optical techniques 
have been recently applied in the clinical practice in view of obtaining qualitatively and 
quantitatively new data from cutaneous neoplasia. Due to their high sensitivity in detecting 
small changes, spectroscopic techniques are now widely used for detection of early changes 
in biological tissues. Fluorescence detection of normal and abnormal tissues is among the 
most promising such approaches as it makes use of naturally existing fluorescent molecules 
(in the case of autofluorescence) or added fluorescent markers (in the case of exogenous 
fluorescence) of high importance. Fluorescent markers are introduced wherever native 
fluorescence is not informative enough to be used for diagnostic goals due to the absence or 
non-specificity of the changes in the tumour vs. the normal tissues.  
The fluorescent diagnostic techniques are particularly suitable in diagnosing melanin-
pigmented cutaneous pathologies. Melanin is a pigment which absorbs strongly within 
practically entire visible spectral range. Its high content in these lesions leads to low 
penetration depth of the excitation light and a small amount of re-emitted fluorescent light 
that can be collected and used for fluorescent analysis of the pathology under investigation. 
Therefore, fluorescent diagnosis of melanin-pigmented neoplasia, such as cutaneous 
malignant melanoma and its differentiation vs. dysplastic precursors and similar benign 
skin pathologies, such as nevi, is an elaborate and challenging task for all researchers 
working in the field of biomedical photonics. Photodiagnosis (PD) and photodynamic 
therapy (PDT) have been established as emerging modalities for a variety of pathogenic 
conditions including pigmented melanoma (Awan et al., 2006; Davids and Kleemann, 2010). 
The number of cases of pigmented malignancies has been steadily increasing during the last 
decades in general, and, in particular, malignant melanoma (MM) incidence has also 
increased. Melanomas are the most aggressively developing form of dermatological cancers 
due to the difficulty of diagnosis at an early stage combined with the low rate of success of 
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the treatment at the late stage. The key factor of success with melanoma disease is an early 
detection followed by effective treatment procedures. PD and PDT could be the proper 
answer in achieving this goal. 
1.1 Autofluorescence of cutaneous melanoma 
Autofluorescence has been proven to be a very sensitive and accurate method for detection 
of early changes in many cancer types; however, due to the specific optical properties of 
melanin, fluorescence spectroscopy application to malignant melanoma detection is still a 
matter of debate. A few attempts have been made to detect fluorescence of melanin itself 
based on natural and synthetic melanin solutions. The authors reported that a major part of 
the excitation energy (>99,9%) in melanin molecules dissipates through non-radiative 
pathways (Lohmann and Paul, 1988; Meredith and Riesz, 2004). The natural fluorescence of 
melanin related to its oligomeric units is of extremely low intensity, with emission spectrum 
in the range 450 – 550 nm (Nighswander-Rempel et al., 2005; Perna et al., 2009). The first 
reports on using fluorescence spectroscopy for diagnostics of melanin-pigmented neoplasia 
were published in the late 80’s and early 90’s (Leffel et al., 1988; Lohmann et al., 1991).  
There is still no universal procedure for photodiagnosis and differentiation between malignant 
melanoma and other melanin-pigmented pathologies. Melanin is known to have unique 
light absorption behaviour, completely different from that of the other organic fluorophores, 
namely, an exponential decrease of the absorption from the UV to the near infrared region 
(Nighswander-Rempel et al., 2005). A great number of studies have been carried out in this 
field obtaining promising results based on autofluorescence and on exogenous fluorescence 
detection of these cutaneous malignancies. Interesting approaches for diagnosis have been 
employed based on the autofluorescence properties of melanoma and its subtypes using 
additional analysis of the spectra detected, or specific algorithms, some of which allow 
relatively high sensitivity and specificity of tumour detection and evaluation (Chiwot et al. 
2001; Borisova, 2006). The authors reported values for sensitivity of 82.5% and specificity of 
78.6% after ultraviolet irradiation of the tumours (Chwirot et al., 1998). 
In our investigations with excitation light with wavelength 337 nm used in autofluorescence 
measurements, the sensitivity obtained was about 77,8% and the specificity of 93,3% 
(Borisova et al., 2008b). Whether melanoma autofluorescence is an appropriate diagnostic 
tool is still debatable. Our investigations did not reveal any significant spectral shape 
changes (Borisova, 2006), only a significant fluorescent signal intensity decrease in the case 
of melanoma. While Lohmann and co-authors (Lohmann et al. 1991) concluded that 
autofluorescence spectroscopy is capable of differentiating melanoma from normal tissue 
using ultraviolet excitation (365 nm), Sterenborg and co-authors (Sterenborg et al., 1995) 
reported that they did not observe a significant correlation between the fluorescence 
emission and the histopathological examination of the lesions studied. Thus, melanoma 
remains a work in progress for non-invasive diagnosis. 
Low-level fluorescent signals distorted by the melanin absorption can be detected in spite of 
the pigment influence on the spectra registered by the means of high-sensitivity detectors, 
which appeared recently in the market (Borisova et al., 2005).The signals detected from 
melanoma lesions originate mainly from co-enzymes and structural proteins (Borisova et al., 
2008a).  
A promising approach based on femtosecond two-photon excitation of melanin was also 
proposed (Teuchner et al. 1999). Despite its potential, this method is very expensive and 
inconvenient to be introduced into the standard clinical practice. 
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1.2 Exogenous fluorescence (photodiagnosis) of cutaneous melanoma 
Another possible way of detection is based on introducing exogenous fluorescent markers in 
the lesions, as melanoma lesions exhibit very low autofluorescence signals. The conventional 
application of a fluorescent contrast agent as a positional marker for detection of malignancies 
appears to be commonly used for diagnosis of pigmented melanoma tumours. 
The exogenous fluorophores called photosensitizers (PS) have found the widest application; 
they are used to improve the fluorescent detection of melanin-pigmented neoplasia. These 
compounds could be used for photodiagnosis, as well for initiation of a photodynamic  
effect in the tumour cell, so that one could combine photodiagnosis with a subsequent 
photodynamic therapy of the lesion. 
Bearing in mind the specific optical properties of melanin, especially its strong absorption  
in the shorter wavelengths’ spectral range, scientists have focused their efforts on the 
synthesis and study of long-wavelengths photosensitizers, such as phthalocyanines and 
naphthalocyanines, which absorb in the 670-760 nm range and fluoresce in the 680 – 800 nm 
range (Woehrle et al., 1999; Peeva et al., 1999; Shopova et al., 1999; Mantareva et al., 2005). 
The incident light must be of appropriate wavelength to ensure deep penetration in order to 
excite the native tissue chromophores of the malignant tissue. The diagnostic light usually 
covers the part of visible spectra (488-635 nm) where the so called endogenous sensitizers 
absorb strongly. The fact that the absorption spectra for normal vs. pathogenic tissues are 
different is a useful tool allowing fast diagnosis (Borisova et al., 2005). The application of 
exogenous chromophores can enhance the images and can further assist the therapy. It is 
important that the applied light’s wavelength to be shifted away from the absorption peak 
of the tumour localizing photosensitizers, so that detection at both wavelengths should be 
possible. Recently, PSs that possess the properties of good tumour tissues uptake and 
retention for fluorescent detection and relatively high photochemical parameters of singlet 
oxygen generation and other ROSs were defined as theranostic drugs (Rai et al., 2005). The 
appropriate use of the competitive approaches after light excitation is limited by the 
absorption coefficients of the native chromophores of tumour cells and by the light 
scattering properties of the constituents of the tumour tissue. External to the tissue natural 
or synthetic photosensitizers that would allow large intensity fluorescence demarcation and 
powerful photosensitizing processes are still under development. 
1.3 Photodynamic therapy of cutaneous melanoma 
Besides the initial diagnosis of the pathology, an important clinical aspect is related to the 
following treatment and therapeutic modalities, which could be applied on sensitive and 
severe skin lesion, such as malignant melanoma. The photodynamic therapy modality is a 
curvative tool developed and applied in the clinical practice in the last few decades, 
whereby photosensitizers absorbing in the near-infrared spectral region and selectively 
accumulated in tumour tissue transfer their energy after light irradiation to the surrounding 
oxygen and produce singlet oxygen, which then reacts with and destroys adjacent proteins 
and lipids in the cell membrane structures, or switches on the processes of apoptosis in the 
tumour cells. These compounds can also fluoresce; this combination of a possibility for 
photodetection and the following photodynamic effect of the drugs developed for 
photodynamic therapy applications is very promising and useful for the clinical practice.  
The photodynamic approach appears as a complementary methodology which is not 
developed for pigmented melanomas (Mac Donald et al., 2001). The PDT is based on a 
photoactive compound (photosensitizer, PS) and a proper light excitation, together with the 
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presence of molecular oxygen (Dougherty, 1992). As soon as selective localization of PS into 
the tumour tissue occurs, visible light must be applied locally to provoke the photophysical 
mechanisms of excitation of the singlet and triplet states of PS, the latter being metastable 
and can be involved in chemical reactions. The transfer of the light energy absorbed by the 
tissue or only by the PS can take place through radiative decay of the singlet state 
(fluorescence), which is used in non-invasive diagnosis. The same PS can undergo non-
radiative relaxation to the lower energy triplet exited state of PS, which can participate in 
chemical reactions with the surrounding molecules. Basically, two mechanisms of 
photosensitization have been established (Foote, 1991). The more important one takes place 
via an energy transfer from the triplet PS to the ground state of molecular oxygen from 
atmospheric air, which results in the formation of highly cytotoxic singlet oxygen. The 
process is known as mechanism type II of photooxidation. Concurrently, the mechanism 
takes place of an electron or proton transfer from the excited triplet PS to the surrounding 
tissue molecules. As a result, reactive oxygen species (ROSs) are generated. This is known as 
mechanism type I of photosensitization. 
Diverse results have been reported on the application of exogenous photosensitizers.  
PDT appears to be a promising new approach for an early detection and sufficient therapy 
of the most aggressive forms of cancer, such as pigmented melanoma tumours. The 
clinically approved photosensitizers are the porphyrin derivatives (Photofrin ® and 
Haematoporphyrin derivative) and aminolevulinic acid (ALA) which is a precursor of the 
porphyrin-like compound protoporphyrin IX. However, the so-called first generation 
sensitizers exhibit the disadvantage of optical limitation which precludes the application of 
the existing drugs to the diagnosis and treatment of pigmented melanomas. The difference 
in the ALA-induced protoporphyrin IX autofluorescence (excitation at 365 and 405 nm, 
emission at 635 nm) from malignant melanoma as compared with healthy skin in humans 
appears to be related to the different oxygenation rather than to the specificity of the 
fluorophores of malignancies. The fluorescence-based detection of abnormal tissues during 
the therapy is based on temporary differences in the kinetics of drug uptake between 
normal and malignant cells. At present, 5-aminolevulinic acid (ALA, with commercial name 
Levulan®) is used for the formation of protoporphyrin IX. The product of the haem 
biosynthesis is being considered as a drug for fluorescent diagnosis. The further 
development and evaluation of advanced fluorescent contrast agents is an important 
research topic which could lead to a successful solution of many fundamental scientific 
problems. Unlike other primary cutaneous malignancies, melanoma has a strong tendency 
for proliferation; some authors (Allison et al., 2006) even consider that local treatment by 
photodynamic therapy or any other local treatment modality prior to sentinel node 
procedure for evaluation of lymphatic metastasis is contraindicated. As the survival is based 
generally on the successful immunomodulation on a system level, local photodynamic 
therapy would only be a part of the treatment procedures. The photodynamic therapeutic 
immunomodulatory effect achieved seems to be very important in the evaluation of the PDT 
effect in the local control of the lesion and on the survival rate in general (Saczko et al., 2005; 
Allison et al., 2006; Kaplan et al., 2008). This effect is still under investigations and a large 
amount of work remains to be done. 
The further development of PDT agents leading to the development of a second generation 
of far-red absorbing photosensitive dyes with improved spectral properties was the aim of 
our research in recent years (Borisova et al., 2005; Wohrle et al., 1999, Mantareva et al., 2005). 
The new photodynamic drugs were designed to become more efficient contrast agents for 
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fluorescence diagnosis of early-stage malignancies, and especially of pigmented melanomas. 
Other researchers have also reported very promising results from PDT treatment of pigmented 
melanoma with a new generation of photosensitizers making melanoma cells highly 
sensitivity to the PDT (Davids and Kleemann, 2010; Kolarova et al., 2007a; Kolarova et al., 
2007b). PDT treatment with a new generation of photosensitizers was also proposed to be used 
as an additional palliative procedure for patients with malignant melanoma (Kubler, 2005). 
A part of our own research interests were the highly conjugated macrocyclic complexes 
from the group of tetra-isoindoles, such as phthalocyanines and naphthalocyanines. 
Phthalocyanines are characterized by a red-shifted and strong absorption maximum (> 670 
nm) as compared to porphyrins (~ 630 nm). The zinc(II) coordinated complexes were 
studied as efficient fluorescent contrast agents of an experimental B16 pigmented melanoma 
on mice. Several cationic Zn(II)-phthalocyanines (ZnPcRs) with different hydrophilic/ 
lipophilic balance were synthesized and studied as promising diagnostic agents for 
pigmented melanoma. It was shown that the long wavelength absorption together with a 
high fluorescence intensity at the wavelength over 680 nm as well as the selective tumour 
cells uptake as compared to the surrounding normal tissue result in two advantages over 
the porphyrins and derivatives. The additional benzene rings lead to extended Pc analogues 
such as naphthalocyanines. They have the advantage of a stronger and deeper far-red 
absorption (760-790 nm) than phthalocyanines. A number of in vivo studies on B16 
pigmented melanoma treated with Si(IV)- and Zn(II)-naphthalocyanines at different 
therapeutic protocols showed the potential value of the PDT approach when combined with 
some other methodology.  
The clinical acceptance of the method was achieved in 1998 for treatment of non-pigmented 
tumour localizations with porphyrin derivatives (Haematoporphyrin derivative, Photofrin) 
and aminolevulinic acid (ALA) by application of visible light at 635 nm (Brown et al., 2004). 
The porphyrin derivatives and ALA, which is a precursor in the biosynthesis of 
protoporphyrin IX, have shown low efficiency for pigmented melanomas (Ibbotson, 2010). 
This was explained by the overlapping of the absorption spectra of the melanin pigment and 
porphyrins. The low transparency of the pigmented tissue at the excitation wavelength 
typical for porphyrins (around 630 nm) minimized the photosensitizing process efficiency. 
The pigmented melanomas are known as being weakly affected by the so called first 
generation photodynamic sensitizers, which are porphyrin based molecules (Kalka et al., 
2000). An ideal PS for tumours needs to absorb at longer wavelengths to be suitable for 
treating melanomas with pigments. The so-called second-generation PSs were developed to 
have improved physical, chemical and spectral properties. The representative groups of PSs 
are the pheophorbide derivative, chlorine-type molecules like benzoporphyrin monoacid 
derivative (Verteporfin), and more extended macrocycles such as phthalo- and naphthalo- 
cyanines (sulfonated MPcs, Photosense). These PSs have energy absorption band in the far 
red spectral region (> 660 nm) with high absorption coefficients which allows a deeper 
tissue penetration of the excitation light, enabling it to penetrate blood, melanin and fibrotic 
tissue. 
The studies in our laboratory on highly pigmented variety of malignant melanoma B16 
demonstrated an effective diagnosis and PDT response by using phthalocyanine and 
naphthalocyanines metal complexes (MPcs and MNcs) with intensive far red absorption 
band (Michailov et al., 1997; Peeva et al, 1999; Mantareva et al., 1997; Woehrle et al., 1999). 
The competition for the absorption of melanin with the applied light decreases as a single-
exponent when the wavelength is increased (Mantareva et al., 2005). These photosensitive 
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compounds are characterized by a large molar extinction coefficient (1-5 x 10 5 M-1 cm-1) in 
the spectral range around 675 nm (MPcs) and 770 nm (MNcs) where the pigmented 
melanomas have minimal absorption (Sounik et al., 1990).  
1.4 PD and PDT of melanoma – applications 
In view of improving the early diagnosis and the differentiation of risk lesions, we proposed 
a method of evaluating the autofluorescent characteristics of several common cutaneous 
benign and malignant lesions. Pigmented melanoma may simulate benign lesions, including 
seborreic keratoses, heamangioma, compound and dysplastic nevi. Amelanotic malignant 
melanoma may clinically mimic a basal cell carcinoma. All these pathologies were investigated 
and their fluorescent spectra and specific features were evaluated vs. malignant melanoma 
pathologies for development of a broad clinically valuable algorithm for melanoma detection 
based on the autofluorescent properties of skin lesions. The origins of diagnostically significant 
spectral features were discussed. The differentiation algorithm of benign/dysplastic/ 
malignant pigmented skin melanin-pigmented lesions proposed allowed us to differentiate 
MM with sensitivity about 78% and specificity more than 90 %. These numbers give a 
diagnostic accuracy of about 70% using the autofluorescence signals received.  
To improve the diagnostic accuracy, exogenous photosensitizers need to be applied. A large 
number of experiments have been already carried out using photosensitizers from the 
phthalocyanines group (Mantareva et al., 2005). These compounds have very promising 
optical properties in terms of fluorescence quantum yield and photodynamic properties and 
high selectivity to the tumour cells. Cationic phthalocyanines differing in their lipophylicity 
were studied as long-wavelength absorbing fluorescent markers for pigmented melanoma 
tumour on a model animal (mice) (Fig. 1). In order to study the transport through the 
cellular membranes, lipophilic and hydrophilic Pcs were prepared. Their fluorescence 
behaviour was studied in solutions (dimethylsulfoxide) (Fig. 2) and in turbid media 
(incorporated into the cells). In vivo fluorescence detection studies showed a higher in situ 
discrimination of the tumour from the healthy surrounding tissue compared with the 
commonly used drugs. The limitations of pigmented melanomas detection when using ALA 
can be avoided by using cationic phthalocyanine complexes with a proper hydrophilic/ 
lipophilic balance. The proposed experimental fluorescence spectroscopy technique (Fig. 3) 
is suitable for clinical application in fluorescence detection of pigmented malignancies. In 
vivo fluorescent diagnostic potential of the studied compounds concerning pigmented 
melanoma was demonstrated, so that clinical studies on humans are foreseen in our long-
term plans with the purpose of introducing photodiagnostics and photodynamic therapy of 
malignant melanoma. 
Both autofluorescence and exogenous fluorescent detection have their place in the clinical 
practice. The former method could be used as a screening tool for initial detection and 
evaluation of cutaneous pathologies, while the latter must be applied on suspicious cases, 
where it could be used as an affirmative test of the initial diagnosis, as well as a tool for 
photodynamic therapy of the neoplasia, if such is diagnosed as cutaneous pigmented 
melanoma.   
2. Chemistry of phthalocyanines as photosensitizers for pigmented 
melanoma 
During the last decades of intensive research on PDT with phthalocyanines, several of them 
were proposed as potential candidates for second generation photosensitizers. In concerns 
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of their chemistry, the strong lipophilic and aggregation properties of the macrocycle 
facilitate the proper tailoring of the Pcs structure. 
Most of the well-known Pcs under physiological conditions are insoluble, unstable to light 
and tend to form dimers and higher aggregates which leads to a dramatic decrease of 
photochemical properties of the generation of ROSs and, in turn, the PDT effectiveness. 
Overcoming these limitations is the crucial factor for potential clinical applications. A 
number of suitable substitutions on the peripheral position of the ring, as well as axially to 
the coordinated metal ion have been devised and tested by in vitro/ in vivo experiments.  
Several Zn(II) naphthalocyanines with differing  substituents (amino-, amide-, sulfuric acid -
groups) and Si(IV) with methoxyethylenglycol axial substitution were studied in our group 
(Mantareva and co-authors, 1997, 1999, 2005). The results showed that after incorporation of 
liposome vesicles ZnNcA, which has four benzamido-substituents, had a high photodynamic 
response for B16 pigmented melanomas. 
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Fig. 1. Chemical structure of Zn(II)-phthalocyanine with pyridyloxy substituents with 
increasing hydrocarbon chain to N-atom 
The coordinated with silicon (IV) naphthalocyanine axially substituted with 
polyethyleneglycol (SiNc) was synthesized and studied as promising for PDT of B16 
pigmented melanoma (Mantareva et al., 1997; Woehrle et al., 1999). Other authors have 
studied Si(IV) naphthalocyanine (isoBO-SiNc) for PDT of B16 pigmented melanoma with 
pretreatment by high-peak-power (HPP) laser 1064 nm irradiation, which enhanced the 
tumour susceptibility to conventional PDT (Sounik et al., 1990; Busetti et al., 1998). 
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3. Absorbance of melanin and other tissues’ chromohores vs. 
phthalocyanines 
The strong absorption in the red and far-red region of the visible spectrum ensures deeper 
light penetration that does not depend on the melanin pigment. The typical absorption 
spectrum of Pcs is characterized by a strong Q-band around 675 nm and with a half as 
intensive Soret band, which lies around 350 and 360 nm (Fig. 1). By adding substituents, the 
position of the maxima can vary by 5-8 nm, to the red with increase of the molar absorption 
coefficients. We studied the absorption spectra of endogenous chromophores which are 
good absorbers of visible light (Mantareva et al., 2005). Figure 2 presents the spectra of 
natural chromophores such as riboflavin, hemoglobin, cytochrome C and melanin extracted 
from B16 pigmented melanoma.  
 
 
Fig. 2. Absorption spectra of Zn(II)-phthalocyanine (DMSO) and native tissues chromophores  
(hemoglobin, riboflavin, cytochrome C, all in saline) vs. melanin (1N NaOH) (Mantareva et 
al., 2005) 
Melanin showed a mono-exponential decrease of the absorption from the UV to the near IR 
region (300-800nm). The absorbance of unsubstituted ZnPc is typical for phthalocyanines. 
There is only a limited overlapping of the spectra of native chromophores and ZnPc as a 
photosensitizer. When the excitation light is not in the region of the absorbance of the tissue, 
light is not interacting with the tissue pigments, all light energy can be absorbed by the 
photosensitizer localized in a pigmented melanoma tumour. Two optical processes that 
influence these effects must be taken into account, namely, malignant tissue’s absorption 
and light scattering. Both are known to decrease while the wavelength is increased (635-
850nm). In the case of a deeply pigmented tumour tissue, such as B16 pigmented melanoma, 
the absorption by melanin even in the far-red region (>700nm) is not negligible. The melanin 
absorption reduces the depth of light penetration and further limits the effect of 
photodiagnosis and therapy. The depth of light penetration and the light scattering are 
recognized as crucial for to controlling the response of tumours to PDT. In our previous 
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work with naphthalocyanines, we showed the strong absorbance (776 nm, 5 x 105 M-1 cm-1) 
of these compounds and a successful treatment of B16 pigmented melanoma implanted in 
mice (Mantareva et. al., 1997; Peeva et. al., 2001). However, the PDT effect was still 
incomplete, probably as a result of the low drug selectivity and the insufficient light 
penetration to the deeper pigmented melanoma layers. 
4. Photobiology of B16 pigmented melanoma 
4.1 Uptake study 
The uptake study of the group of phthalocyanines with increased hydrophobicity 
depending on the attached hydrocarbon chain to the methypyridyloxy group (ZnPcMe, 
ZnPcPr, ZnPcHe and ZnPcDo) was carried out by the experimental set-up, which is 
presented on Fig. 3. 
 
 
Fig. 3. The experimental set-up for fluorescence determination of photosensitizer uptake 
(Mantareva et. al., 2005) 
The samples of B16 melanoma cells were incubated with respect to ZnPcs (1.6 µM and 2.3 µM) 
and the fluorescence was measured after tissue chemical extraction. The data showed the 
amount of dye per mg tumour mass (Fig 4). The time-dependence curves were obtained 
within a 6-hour follow-up period. The results showed that the maximal amounts of ZnPcs in 
the pigmented melanomas tissue (between 2.3-7.1 nmol mg-1) as compared to the 
surrounding skin/ epithelial cells were reached 90 min after injection. 
Considering the hydrophilic vs. hydrophobic nature of the studied ZnPcs, which were 
evaluated by their partitition coefficients, the uptake results showed a highest uptake in the 
case of an amphiphilic compound (ZnPcHe with 7.1 nmol at 90 min)). The most hydrophobic 
ZnPcDo and the hydrophilic ZnPcMe showed similar accumulation behaviour (2.3 nmol 
and 3.1 nmol). The water-soluble photosensitizer ZnPcMe showed the lowest tumour 
accumulation and the longest retention period (6h). 
The lipophilic ZnPcDo was evaluated with low accumulation during the studied period  
(1-6h). The phenomenon of precipitation of a lipophilic drug under physiological condition 
(pH~7) can provoke an insufficient accumulation into the cells. We found that cationic 
ZnPcs differing in lipophilicity have specific uptake into B16 pigmented melanoma in 
dependence on their hydrophilic/lipophilic nature. 
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Fig. 4. Tumour uptake of cationic ZnPcs into B16 pigmented melanoma cells presented by 
ZnPcs concentration 
 
 
Fig. 5. In vivo fluorescence spectra of healthy (up) and tumour (down) tissues recorded 24 h 
after i.p. injection of  ZnPcHe-DPPC  liposomes.  The fluorescence spectra are taken at 
different excitation wavelengths using an Ar-dye laser source (insets) 
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Fig. 6. Comparison of the spectral signals obtained by in vivo fluorescence detection of 
tumour and healthy tissues recorded 24 h after i.p. injection of ZnPcHe-DPPC liposomes, 
using different excitation wavelengths (Mantareva et al., 2005) 
4.2 Photodiagnosis and photodynamic therapy studies on B16 pigmented melanoma 
In the recent photodynamic studies, we prepared differently substituted  
Zn(II)-phthalocyanines (ZnPcs) to be studied as selective B16 pigmented melanoma cells 
agents. The hydrophobicity of ZnPcs was evaluated with respect to their selective localizing 
properties on a B16 tumour model. We were able to demonstrate the effective diagnosis at 
the early stage of development of pigmented melanoma in an in vivo experiment (Fig. 5 and 
Fig. 6).  
The PDT response of B16 pigmented melanoma implanted on mice was compared for 
different generations of photosensitizers by varying the treatment parameters. The treatment 
of pigmented melanomas with naphthalocyanines was successful. The phototoxicity studies 
performed with liposome-incorporated Zn(II)-phthalocyanine (Ciba-Geigy, Switzerland) 
and tetrabenzamido-substituted Zn(II)-naphthalocyanine, ZnPcA synthesized for PDT 
studies revealed a high PDT response (Peeva et al., 1999; Soncin et al., 1998).  
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4.3 Light dose effects 
The effectiveness for treatment of B16 pigmented melanoma of the long-wavelength 
absorbing benzamido-substituted naphthalocyanine (ZnNcA) was examined due to its 
strong absorption around 774 nm, which allowed light penetration into the pigmented 
tissue. It was demonstrated that the phototoxicity of ZnNcA increased as the irradiance was 
increased up to 380 mW cm-2, which caused extensive tumour necrosis and substantial delay 
in the rate of tumour growth with 40 % cure rate (Michailov et al., 1997). A moderate 
increase of the tumour temperature above the basal value during the treatment can 
contribute to a better phototherapeutic effect (Fig. 7). The temperature increased above 41 °C 
at 440 mW.cm-2 and above the higher irradiance of 440 and 500 mW.cm-2 led to a lower PDT 
response and the possibility of hyperthermia.  
 
 
Fig. 7. PDT with ZnNcA (0.5 mg.kg-1 b.w.) on mice with implanted B16 pigmented 
melanoma as a function of the fluence (exc: 774 nm 24 h after sensitizer administration). 
Tumour response in mice after PDT treatment at a fluence of 360 J cm-2 performed 24 h after 
sensitizer administration (0.5 mg kg- 1 b.w.)  and 30 min after anesthesia (490 µg/g chloral 
hydrate ). (a) Tumours exposed to 774 nm at fluences of 260, 320 and 380 mW cm -2. Control 
groups without sensitizer and irradiation. (b) Tumors exposed to 774 nm at fluencs of 440 
and 500 mW cm -2. To facilitate the comparison, the PDT curve for 380 mW cm-2 irradiation 
is also given (Michailov et al., Copyright 1997, Elsevier) 
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5. Conclusions 
Photodiagnosis and photodynamic therapy are based on the native tissue chromophores 
and on the exogenous photosensitizers, which are deposed preferentially into malignant 
tissues. Excitation with light with appropriate wavelength catalyzes the production of ROSs 
which induces cytotoxic effects causing irreversible photodamage to tumour tissues (Awan 
and Tarin, 2006; Davids and Kleemann, 2010; MacDonald, 2011; Foote, 1991). The data 
collected from preclinical and some clinical observations suggest that the PDT approach 
appears to be useful in numerous oncological malignances (Dougherty, 1992; Allison, 2006). 
Pigmented melanoma is one of the malignancies that are highly aggressive, while the 
known treatment procedures have poor prognosis. In our in vitro/ in vivo studies on B16 
pigmented melanomas, we focused on the improvement of the photosensitizing agents from 
the group of phthalocyanines and naphthalocyanines and on the applied treatment 
protocols (Borisova et al., 2005; Rai et al., 2010; Brown et al., 2004). The principal factor 
which influences the susceptibility of pigmented melanoma to the PDT is the competition 
between the absorbance of melanin from B16 melanoma and the absorbance of the 
photosensitizing agent at the excitation wavelength. The porphyrin derivatives Photofrin 
and HpD have low absorbance at 630 nm where the pigmented tissue absorbs sufficiently; 
as a result, the PDT response of B16 pigmented melanoma was insignificant (Rai et al., 2010). 
The studies with photosensitizers absorbing in the far-red region, namely, phthalocyanines 
and especially naphthalocyanines suggested that the significant level of pigmentation is not 
an obstacle to applying PDT for diagnosis and therapy of highly pigmented tumours, such 
as B16 pigmented melanoma. The combined action of the photosensitizing process and the 
photoinduced hyperthermia can boost the anti-tumour effect. The optimization of the 
treatment modality concerning pigmented melanoma involves the photodegradation of the 
pigment as a first step of treatment and further application of PDT with naphthalocyanines 
or other far-red absorbing sensitizers. 
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